Literature DB >> 675673

Prenatal diagnosis and fetal pathology of Niemann-Pick disease.

S Higami, K Omura, K Nishizawa, T Yamashita, K Tada.   

Abstract

Prenatal diagnosis was successfully accomplished by determining sphingomyelinase activity in the cultured amniotic fluid cells in a case of high risk pregnancy for Niemann-Pick disease (NPD), type A. No detectable activity of sphingomyelinase was found in the cultured amniotic fluid cells obtained at the 17th week of gestation. Patient's pregnancy was terminated and the aborted fetus was proved to be affected with NPD. The liver, brain and skin fibroblasts from the aborted fetus revealed a markedly diminished activity of sphingomyelinase. Sphingomyelin content in the liver of the affected fetus was found to be increased approximately sevenfold as compared with that in a control fetus liver. On the other hand, there was no increase of sphingomyelin in the brain from the affected fetus. No significant increase in cholesterol content was found in the liver and brain from the affected fetus. Electron-microscopic findings revealed membranous cytoplasmic bodies and electron dense material with vacuoles in cytoplasm of the liver cell and a number of Zebra body-like inclusions in the cerebral vessel wall. Biochemical and histological findings of the NPD fetus indicate that there is the progress of the disorder already in the midtrimester of gestation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 675673     DOI: 10.1620/tjem.125.11

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

Review 1.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

2.  Niemann-Pick disease type B: prenatal diagnosis and enzymatic and chemical studies on fetal brain and liver.

Authors:  D A Wenger; T Kudoh; M Sattler; M Palmieri; M Yudkoff
Journal:  Am J Hum Genet       Date:  1981-05       Impact factor: 11.025

3.  Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.

Authors:  Davide Sala; Francesca Ornaghi; Francesco Morena; Chiara Argentati; Manuela Valsecchi; Valeria Alberizzi; Roberta Di Guardo; Alessandra Bolino; Massimo Aureli; Sabata Martino; Angela Gritti
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-16       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.